ClearPoint Neuro receives Nasdaq non-compliance notice, cures by reconstituting committees

ClearPoint Neuro, Inc.

Nasdaq notified ClearPoint Neuro on May 19, 2022 of non-compliance with audit and compensation committee independence rules due to Matthew Klein, M.D. not being independent.
Board reconstituted committees on May 13, 2022: Audit now has Pascal Girin, Lynnette Fallon, R. John Fletcher; Compensation has B. Kristine Johnson and Timothy Richards.
Nasdaq confirmed the company now complies with Listing Rule 5605 following committee changes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.